SHANGHAI : China's CanSino Biologics Inc said on Wednesday that expert opinion on its high-profile coronavirus vaccine candidate should not be followed "blindly" without sufficient clinical trial data.Scientists outside the company have expressed concern that the effectiveness of CanSino's candidate Ad5-nCoV, which is based on a common cold virus to which many people have been exposed, could be limited.
They said existing antibodies against the common cold virus might undermine Ad5-nCoV."Vaccine development is a practice-based science, and we should not blindly follow experts," Zhu Tao, chief scientific officer, said during an investor conference.He said there were instances in which vaccines created using methods doubted by experts had.